JPMorgan analyst Lisa Gill raised the firm's price target on Teladoc Health to $146 from $112 and keeps an Overweight rating on the shares. The company reported "strong" Q4 results, with revenue and adjusted EBITDA again exceeding expectations, as greater than expected membership and visits again drove strong organic revenue growth, Gill tells investors in a post-earnings research note. The analyst continues to point to "significant runway" in the telehealth market and believes Teladoc is "very well positioned as the only comprehensive virtual care delivery solution."